期刊文献+

^(125)I-脱氧尿嘧啶核苷对肺癌细胞A549的杀伤作用 被引量:1

Killing effect of ^(125)I-UdR on lung cancer cell line A549
下载PDF
导出
摘要 目的探讨125I-脱氧尿嘧啶核苷(125I-UdR)对体外培养的A549肺癌细胞的杀伤作用及其影响因素。方法测定A549肺癌细胞在含有不同浓度125I-UdR的RPMI 1640培养液中培养48 h后细胞及细胞核摄取125I-UdR的量;测定肺癌细胞A549及脐静脉内皮细胞(ECV304)在含有100 kBq/ml 125I-UdR的RPMI 1640培养液中培养2~48 h后不同时间细胞摄取125 I-UdR的量;用细胞克隆形成法评价不同浓度125 I-UdR对A549肺癌细胞的杀伤作用。结果 A549细胞和细胞核摄取125I-UdR的量随培养基中125I-UdR浓度增加而增加;在含有100 kBq/ml浓度125 I-UdR的培养液中,随培养时间的延长A549细胞和细胞核摄取125 I-UdR的量增加。在不同培养时间下,A549细胞摄取125I-UdR的量在各时间点均明显高于ECV304细胞的摄取量。细胞存活分数随培养基中125I-UdR浓度增加呈递减趋势。结论 125I-UdR能够被A549肺癌细胞摄取,并快速进入细胞核内,且摄取量存在浓度依赖性和时间依赖性1,25I-UdR对肺癌细胞具有明显的杀伤作用。 Objective To investigate the killing effect of 5-iodo-2′-deoxyuridine(125I-UdR) on lung cancer cell line A549 and the factors of influencing in vitro.Methods The amount of 125I-UdR taken by the cells and caryons were measured through counting the radioactivity after incubating for 48 hours in RPMI 1640 culturing medium containing different concentration of 125I-UdR.The amount of 125I-UdR taken by A549 and ECV304 cells were measured in 100 kBq/ml dosage of 125I-UdR after incubating different time(2-48 hours).The killing effect of 125I-UdR on A549 cell was evaluated by colony forming method.Results The amount of 125I-UdR taken by the cells and karyons increased with the increasing of 125I-UdR concentration.The concentration that A549 and ECV304 cells ingested 125I-UdR was time-dependent among 2-48 hours.The radioactivity concentration of 125I-UdR uptook in A549 cell was evidently higher than that in ECV304 cell in different incubation time.The surviving fraction was gradually decreased with the increasing of 125I-UdR concentration in culturing medium.Conclusions 125I-UdR could be ingested by A549 cell in culturing medium,which showed strong killing effect on the cells.The concentration of 125I-UdR ingestion was influenced by the dose and culturing time.
出处 《山东医药》 CAS 北大核心 2011年第36期40-42,共3页 Shandong Medical Journal
关键词 肺肿瘤 A549细胞 125I-脱氧尿嘧啶核苷 lung cancer A549 cell 5-iodo-2′-deoxyuridine
  • 相关文献

参考文献9

  • 1Makrogirgos GM, Kassis AI, Baranowska-Kortylewics J, et al. Radiotoxicity of 5- [ ^123I ] iodo-2 '-deoxyuridine in V79 cell : a comparison with 5-[ ^125 I ] iodo-2'-deoxyuridine [ J ]. Radiat Res, 1989, 118 ( 3 ) :532-544.
  • 2Schneiderman MH, Schneiderman GS. Radioiododeoxyuridine in cancer therapy: an in vitro approach to developing in vivo strategies [J]. J Nucl Med, 1996,37(4 Suppl) :6S-9S.
  • 3Keough WG, Hofer KG. An improved method for synthesis and purification of ^125I or ^131I labled carrier free 5-iodo-2'-deoxyuridine [J]. J Labelled Comp Radiopharm, 1978,14:83-90.
  • 4李金泉,鲍耀东,周岱,吴翼伟,江一民,王博诚,金坚.^(125)IUdR对人脑胶质瘤细胞SHG44的杀伤作用[J].核技术,2001,24(11):881-884. 被引量:11
  • 5Humm JL, Howell RW, Rao DV. Dosimetry of Auger-electron-emitting radionuclides: report no 3 of AAPM Nuclear Medicine Task Group No. 6 [J]. Med Phys Dec, 1994,21(12) :1901-1915.
  • 6Pomplun E, Booz J, Dydejczyk A, et al. A microdosimetric interpretation of the radiobiological effectiveness of ^125I and the problem of quality factor [ J ]. Radiat Environ Biophys, 1987,26 ( 3 ) : 181 - 188.
  • 7Maas RA, Bruning PF, Breedijk AJ, et al. Iododeoxyuridine labelling of S-phase fraction in fine needle aspirates from breast carcinomas [J]. J Clin Pathol, 1996,49(7) :607-609.
  • 8Humm-JL, Bagshawe-KD, Sharma-SK, et al. Tissue dose estimates following the selective uptake of ^125 I-UdR and other radiolabelled thymidine precursors in resistant tumours [ J]. Br J Radiol, 1991, 64(757) :45-49.
  • 9Mariani G, Collecchi P, Baldassarri S, et al. Tumour uptake and mitotic activity pattern of 5-[ ^125 I ] iodo-2'-deoxyuridine after intravesical infusion in patients with bladder cancer [ J ]. J Nucl Med, 1996,37(4 suppl) :16S-19S.

二级参考文献1

  • 1杜子威,中华肿瘤杂志,1984年,6卷,241页

共引文献10

同被引文献11

  • 1Makrogirgos GM, Kassis AI, Baranowska-Kortylewics J, et al. Ra- diotoxicity of 5- [ 1-125 ] iodo-2 '-deoxyuridine in V79 cell : a compari- son with 5-[ 1-123 ] iodo-2'-deoxyuridine [ J]. Radiat Res, 1989, 118(3) :532-544.
  • 2Sehneiderman MH, Schneiderman GS. Radioiododeoxyueidine in cancer therapy: an in vitro approach to developing in vivo strategies [J]. J Nucl Med, 1996,37(Suppl 4) :6-9.
  • 3Bousis C. Dosimetry on sub-cellular level for intraeellular incopo- rated auger-electron-emitting radionuclides: a comparison of monte carlo simulations and analytic calculations[J]. Radiat Prot Dosime- try, 2011,143(1) :33-41.
  • 4Buchegger F, Vieira JM, Blaeuenstein P, et al. Preclinical Auger and gamma radiation dosimetry for fluorodeoxyuridine-enhanced tumour proliferation scintigraphy with [ 123Ⅰ ] iododeoxyuridine [ J ].Eur J Nucl Med Mol Imaging, 2003,30(2) :239-246.
  • 5Kleeker RW Jr, Jenkins JF, Kinsella TJ, et al. Clnical pharmacolo- gy of 5-iodo-2'-deoxyuridine and 5-iodouracil and endogenous pyrim- idine modulation [ J ]. Clin Phamacol Ther, 1985,38 ( 1 ) :45 -51.
  • 6Chi KH, Wang HE, Chen FD, et al. Preclinical evaluation of lo- coregional delivery of radiolabeled iododeoxyuridine and thymidy- late synthaseinhibitor in a hepatoma model [ J ]. J Nucl Med, 2001,42(2) :345-351.
  • 7Dupertuis YM, Xiao WH, De Tribolet N, et al. Unlabelled io- dodeoxyuridine increases the rate of uptake of [ 125Ⅰ] iododeoxyuri- dine in human xenografted glioblastomas[ J]. Ear J Nucl Med Mol Imaging, 2002,29(4) :499-505.
  • 8Buchegger F, Adamer F, Schaffland AO, et al. Highly efficient DNA incorporation of intratumourally injected [ 125Ⅰ ] iododeoxyuri- dine under thymidine synthesis blocking in human glioblastoma xenografts [ J ]. Int J Cancer, 2004,110 ( 1 ) : 145-149.
  • 9Yang W, Zhao JG, Li XY, et al. Anti-tumor effect of ^125 Ⅰ-UdR in combination with Egr-1 promoter-based IFNc gene therapy in vivo [J]. Radiat Environ Biophys, 2010,49(4) :705-714.
  • 10Tan G, Wang Z, Zhang X, et al. Induction of CTLs by DCs pulsed with K-ras mutantpeptide on the surface of nanoparticles in the treatment of pancreatic cancer[ J]. Oncol Rep, 2011,26 ( 1 ) :215- 221.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部